An early-stage seed fund focuses on seed stage and sometimes Series A. Typical equity allocations range from $500 – 750 K per company. The firm is open to both leading and co-investing. The firm has been investing from a $50M fund and is currently raising a new fund, from which it expects to make new investments. The firm is seeking opportunities from across the US with a focus on the Bay Area.
The firm invests across multiple industries including healthcare IT. The firm prefers products that do not require FDA approval. Within healthcare IT, the firm considers both consumer-facing and enterprise solutions that demonstrate customer traction and large market potential.
The firm can work with incomplete management teams and would require a board seat on a case-by-case basis. The firm has funded companies in which the founders were either current students or recent graduates from top US universities.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA-Based VC Invests in Seed Stage, Consumer-Facing and Enterprise Technologies in Digital Health
7 JanHot Investor Mandate: Newly Established Investment Arm of Health System Invests in Digital Health Technologies With Strategic Alignment
7 JanA newly established investment funding arm of a USA-based non-profit health system seeks to foster the commercialization of internal ideas as well as external innovation. The firm made its first investment in September 2020, and expect to close 2 more investments in the next 3 months. To date, the firm has been focusing in Series A to B rounds but expect to look into more early-stage opportunities in the future. Initial size of investment can range from $500K – 1M. The firm invests off balance sheet and has no dedicated fund. The firm is focused on partnering and investing in companies based in the USA.
The firm is interested in piloting and investing in technologies that strategically align with the interests of a large integrated delivery network. This includes both the organization’s existing priority areas, along trying to improve the firm’s strategic position in the future. Areas of interest include improving the ratings and member retention in their Medicaid and Medicare Advantage insurance plans, recruiting and retaining clinicians, process optimization, the coming consumerization of healthcare, back-office optimization, and more. The firm is primarily looking for digital health solutions, but will consider some 510k medical devices. The firm is not interested in therapeutics or diagnostics.
The firm has no specific company or management team requirements. The firm prefers to co-invest alongside syndicate partners.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Investment Arm of Europe HQ Corporate Invests Over $10M in Diagnostics and Monitoring Device Companies in USA, Europe and China
7 JanA corporate venture capital arm of a Europe-based corporate is focused on financial returns as well as bringing strategic value to the corporate. The firm makes equity investments in seed through growth rounds ranging from €1M-€5M for typical initial investments and may invest up to €10M-€12M over the life of the investment. The firm will lead, co-lead or follow and typically seeks a 10%-25% stake in the company. The firm is currently investing out of its third fund of €150M with a total of €450M AUM, and makes 10 investments per year. The firm focuses on North American, European, Chinese and Israeli companies.
The firm is only interested in diagnostics and monitoring devices with a particular interest in point-of-care diagnostics. Recent investments include an autonomous, mobile robot with delivery tracking software and a PCR-based diagnostic instrument for rapid pathogen detection, a connected blood glucose monitor and an enhanced PCR technology (laser PCR). The firm does not invest in traditional biopharma therapeutics and/or medical devices which require FDA approval.
The firm will work with all management teams, including first time entrepreneurs, and requires at least an observatory board seat with most investments requiring a standard board seat with voting rights.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Life Sciences VC With $1B AUM Invests in Therapeutics, With Strong Interests in Oncology, CNS, Rare Diseases, and More
7 JanA life sciences venture capital and company formation firm is currently investing from its second fund and has over $1B AUM. The firm will make equity investments of approximately $10–25 million across all stages of private financing and can either lead investments or co-invest. The firm considers investment opportunities worldwide.
The firm invests primarily in therapeutics and invests broadly across different therapeutic areas and modalities. Areas of high interest include precision medicine approaches, gene therapy, autoimmune diseases, oncology, neurology (particularly diseases with genetically defined populations), ophthalmology, and rare diseases. The firm generally invests from late preclinical (1–2 years pre-IND) through to Phase II, and prefers to invest in assets with good animal models and/or genetic evidence to support efficacy and target validation.
The firm generally invests in privately held companies and likes to work with experienced management teams who have had prior startup successes. The firm is an active investor and the partners have deep experience in company building, and we are therefore interested in providing support on strategy, BD, recruiting and other areas of active management in addition to providing capital.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Make a Match that Matters
17 DecBy Claire Jeong, Vice President of Investor Research, Asia BD, LSN
You’ve likely heard it said that fundraising is a numbers game – this is true, but only half of the equation. It doesn’t matter how many investors you meet with if they are not a fit for your product and stage of development. In fact, the argument can be made that, although networking is inherently valuable, you waste time by not seeking out the right investors for you.
At Life Science Nation (LSN), the mission is to connect companies with capital, and that happens through many ways, but most importantly, through addressing the bottleneck of connecting fundraising founders with investors who are a fit. One of the most direct and powerful methods LSN delivers this is through the Innovator’s Pitch Challenge (IPC).
The IPC puts fundraising founders in front of relevant investors seeking assets in their stage and sector directly through a live pitch session with Q&A, as well as indirectly via a dedicated webpage hosting a long-format pitch video, as well as executive summary, pitch deck, and any supporting materials. Attendees have the opportunity to vote for best pitch, awarding the top three companies with free tickets to future RESI conferences to support their fundraising efforts.
December 18 is the deadline to apply for the Innovator’s Pitch Challenge at 3-Day Digital Redefining Early Stage Investments (RESI), taking place, January 11-13, 2021 as a part of LSN’s Healthtech Partnering Week, January 11-15, 2021. Applications are free, however, applicants are required to register for the conference, as well as pay an additional $500 pitching fee. Early bird pricing ends this week, so get your application in by December 18 and save!
Example of a Company’s Landing Page
See What Investors Are Saying about The Innovator’s Pitch Challenge
|
William Kuziel, MedPro Investors
Mayank Taneja, OSF Healthcare
Nat Brinn, VC23
Gary Gershony, Life Science Angels / BayMed Venture Partners
|
Successful Partnering: It Depends on You, but You’re Not in it Alone
17 DecBy Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN
Life Science Nation (LSN)’s Redefining Early Stage Investments (RESI) conference series enables fundraising executives to network and make connections with key industry players. Because of its unique focus and format, RESI presents valuable opportunities for early-stage companies to meet and partner with investors and strategic partners. However, even with the best systems, partnering can be challenging and competitive.
The conference format has changed radically this year. RESI has evolved from a 1-day, in-person conference to a 3-day digital conference with non-stop partnering serving a global community. Additionally, LSN has added new conferences taking place within Healthtech Partnering Week: 4D Meets AI and Longevity, Health & Innovation, providing five full days of partnering.
LSN partnering events are designed to match fundraising executives with investors who are a fit for their product and stage of development, however, while some companies are consistently successful at getting many good investor meetings at each and every RESI conference they attend, while others struggle to get any meetings at all.
So what is the key to success?
Clearly, your degree of success is directly proportionate to the effort you put into it. There are 4 key elements to successful partnering:
- Create a compelling and complete profile for your company and yourself on the Partnering Platform
- Spend time on developing an outbound meeting request message
- Request as many meetings as possible
- Follow up frequently
Yes, this is a big task and a lot of work over the weeks leading up to a conference, but the effort you put into partnering will determine the outcome. Let’s have a look at each key element of your partnering strategy.
PROFILE
- Start with brief overview, similar to your “elevator pitch”, that simply introduces your company and describes what you do and what makes you special.
- Complete all of the sections in the profile with concise information that investors can easily navigate. The sections to complete are:
-
- Technology Overview
- Alliances and Collaborations
- Supporting Metrics or Evidence
- Current Financing Needs
- Current Investors
- Current Timeline
- IP Status
- Management Team Highlights
- Recent milestones
- Personal profiles of attendees at RESI
- Upload your logo, your website and any supporting materials for investors to review, like an investor deck and executive summary
OUTBOUND MEETING REQUEST MESSAGE
Make your message compelling, as this is what the investor is going to see before deciding whether to look at your profile in more depth. Include the key points, without making it so long that you lose the interest of the reader. The key elements should include the following:
- Introduce yourself, your title, and the name of your company. Although obvious, you might be surprised by how many people don’t do this.
- Introduce your company. Give a brief overview of your company so that an investor can determine from the first sentence whether you are a fit for their investment mandate. Here are five key data points that are likely to affect investor fit:
-
- Where your company is based
- What sector your company is in (biotech, medtech, diagnostics, digital health, etc.)
- The indication you are treating or problem you are trying to solve
- Your product’s stage of development
- Key value proposition/elevator pitch. Use the next part of the email to describe the key value proposition of your technology. This should include a high-level description of the core technology and its major differentiators from currently available products or solutions. This is the core of your messaging and should reveal enough information to grab the investor’s interest.
- Stage of your fundraising You should clearly state where you are in the fundraising process (beginning, middle or end) and what the use of those proceeds will be. This way an investor can gauge if your round is a fit for their capital allocation.
- Reaffirm. You should do your homework on every investor you reach out to and reference a relevant data point to reaffirm the reason you are reaching out.
- Request the meeting.
REQUEST MANY MEETINGS
Keep in mind that investors are juggling their own agendas and are in high demand. Use the RESI Partnering Platform to determine which investors are a fit for you, and request meetings with all of those that you target. Our data show that the fundraising companies that get the most meetings sent out upwards of 50 invitations.
FOLLOW UP FREQUENTLY
A common pitfall in partnering is to not follow up sufficiently until you achieve your goal: to get that investor meeting. It is usually not sufficient to send a meeting request out and just wait for the answers to come rolling in.
The best strategy is to begin your outreach as soon as the Partnering Platform opens. This will give you time to follow up sufficiently with investors you want to meet with. After sending out all of your initial meeting requests, wait for about a week. At that point, send a message through the Partnering Platform using the “SEND A MESSAGE” option to all those who have not answered you after a week, and change your messaging a bit, perhaps focusing each of your follow-up messages on a different area of your company (technology, market and unmet need, management or advisory team, etc.). Be organized and persistent. Use the platform messaging option, email (if you have Premier Partnering), LinkedIn, telephone… whatever it takes to get a response back.
If you follow these steps, you will see the results and have a better partnering experience.
HAPPY PARTNERING!
Angels and Family Offices Funding Diseases that Impact Longevity: A Perfect Fit
17 DecBy Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
The What’s Next Longevity Innovation Summit, organized by Mary Furlong & Associates took place December 3-4, 2020, and hosted a panel highlighting how angel groups and family offices impact innovation within diseases affecting longevity. The panel revolved around how early-stage technology firms are developing and funding products aimed at well-known diseases that disproportionately affect aging Baby Boomers. These conditions range from arthritis, hearing and vision impairment, diabetes, cancer, mental health conditions, chronic respiratory diseases (CRDs), and central nervous system (CNS) diseases.
Angels and family offices want to participate in this market and provide alternative sources of early-stage capital to help launch these new technologies that will help find treatments for these ailments. There is a bevy of new age-tech products and services impacting the market and changing the landscape of aging. These two early-stage investor types are distinct from each other in many ways, but also work well together.
Learn how these investor types operate from prominent early-stage angels and family offices, as they discuss how private capital pools are working together to fund technology and products impacting longevity through healthcare innovation.
Want to join the conversation? Life Science Nation and Mary Furlong & Associates have teamed up to bring investors and early-stage companies working in the longevity market together for a virtual partnering event, January 14-15, 2021. There’s still time to sign up for Longevity, Health & Innovation and start meeting fundraising goals for the new year!


“The Pitch Sessions are a great opportunity to connect with startup CEOs and learn more about their work…It really has been an effective and efficient way to make connections, create deal flow and help startups raise money for their upcoming raises.”
“I look forward to LSN’s events because they provide an opportunity for our venture capital firm to find promising companies with exceptional technologies. The organization and technology platform make it very easy to hear numerous pitches from founders.”
“The Pitch Sessions were a great opportunity to engage with the CEO/Founders of very innovative Life Science startups. Despite the COVID-related transition from in-person to virtual meetings, the RESI team did an outstanding job organizing these sessions, ensuring that the live Q&A was very productive, and facilitating follow-up with these exciting companies.”





